Document
RDF description of Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. - http://irises.uniss.it/resource/item/3997
Academic Article
Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
Generically Dependent Continuant
Article
Information Content Entity